CMS (00867) announced on October 27, 2025, that its subsidiary has signed a distribution agreement with Novartis Pharma Services AG for the ophthalmic drugs Lucentis® (Ranibizumab Injection) and Beovu® (Brolucizumab Injection). Under the agreement, the group secures exclusive rights for import, distribution, sales, and promotion of these products in mainland China, while Novartis remains responsible for manufacturing and supply. The collaboration is set for a five-year term starting from the effective date specified in the agreement.

Novartis AG, headquartered in Basel, Switzerland, is a globally renowned pharmaceutical company focused on four core therapeutic areas—cardiovascular, renal & metabolic diseases; oncology; immunology; and neuroscience—as well as five key technology platforms, including chemotherapy, biologics, xRNA therapy, radioligand therapy, and gene & cell therapy.

This partnership is expected to enhance the overall competitiveness of CMS’s ophthalmic business unit, CMS Vision. With existing coverage in retinal diseases, eye fatigue, and glaucoma, the addition of Lucentis® and Beovu® will synergize with CMS Vision’s current portfolio, including the exclusive drug Stulln® (Esculin and Digitalis Glycosides Eye Drops) and the EyeOP1 glaucoma treatment device. The collaboration will strengthen academic branding, drive development of innovative ophthalmic products, and expand treatment options for patients.

CMS Vision’s specialized team will further integrate market channels and academic resources to improve operational efficiency, with a positive impact anticipated on the group’s financial performance.